In the past, because growth hormone could not be produced in China, many families of short children could not treat their children because the imported growth hormone was too expensive. From 65438 to 0998, Jinsai Pharmaceutical Co., Ltd. produced the first recombinant human growth hormone powder injection, which successfully filled the domestic gap and ended the monopoly of importing recombinant human growth hormone in China. At the same time, based on China's national conditions, the annual treatment cost of patients was reduced to 20,000-30,000 yuan.

From imitation to innovation, Kinsey Pharmaceutical has reached high global standards. The incidence of adverse reactions caused by molecular polymerization of growth hormone freeze-dried powder injection is high, which is a very big product "pain point" Four years later, in 2005, the first recombinant human growth hormone injection in Asia went on the market. At that time, this huge technical barrier shut out many domestic and foreign counterparts.

The pace of innovation in Jinsai Pharmaceutical has not stopped. They focus on another polyethylene glycol technology. Simply put, it is to put on an inert hydrophilic polymer "coat" outside protein, and realize long-term and sustained drug delivery by stably controlling the process of "taking off the coat". In 20 14, the world's first pegylated long-acting recombinant human growth hormone came out for the first time, and the number of injections needed by patients was reduced from 365 times a day to only 52 times a year, ending the world's 60-year treatment history and greatly improving the compliance of patients.

Facts have proved that "jacket-style" long-acting growth hormone can simulate the biological effect of human physiological pulse better than short-acting growth hormone, and its compliance and safety are more obvious. Kinsai Pharmaceutical, a long-acting growth hormone technology representing "Made in China", is at least five years ahead of the world.